Feb 24, 2020
Precigen to Announce Fourth Quarter and Full Year 2019 Financial Results on March 2nd
Jan 02, 2020
Intrexon To Achieve $175M Cash Goal, Appoints Helen Sabzevari, PhD, As New President And CEO And Will Change Name To Precigen To Reflect Healthcare Focus
Nov 18, 2019
Triple-Gene Presented Preliminary Phase 1 Trial Data of Investigational Multigenic Therapeutic Candidate INXN-4001 for Treatment of Heart Failure at American Heart Association Annual Meeting
Nov 07, 2019
Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN-4001, First Multigenic Investigational Therapeutic Candidate for Treatment of Heart Failure
Nov 04, 2019
Intrexon to Announce Third Quarter Financial Results on November 12th
Aug 19, 2019
ActoBio Therapeutics(TM) Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients' Tolerance of Gluten
Jun 13, 2019
Intrexon's Subsidiary Precigen to Present at the JMP Securities Life Sciences Conference
May 28, 2019
Intrexon to Participate in 2019 BIO International Convention
May 13, 2019
Intrexon to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference
May 09, 2019
Intrexon Reports First Quarter 2019 Financial Results
May 02, 2019
Intrexon to Release First Quarter 2019 Financial Results on May 9th
Apr 29, 2019
Intrexon and Xogenex Present at American Society of Gene and Cell Therapy Annual Meeting
Feb 28, 2019
Intrexon Reports 2018 Fourth Quarter and Year End Financial Results
Feb 20, 2019
Intrexon's Subsidiary Precigen to Present at the SVB Leerink 8th Annual Global Healthcare Conference
Jan 15, 2019
Intrexon Partners with Next Green Wave to Advance Intrexon's Botticelli(TM) Next Generation Plant Propagation Platform into Development for Cannabis
Jan 02, 2019
Intrexon Announces Presentations at Upcoming Investor Conferences
Dec 31, 2018
Precigen to Debut Portfolio at Investor Event during the 37th Annual J.P. Morgan Healthcare Conference
Dec 21, 2018
Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for First-in-Class PRGN-3006 UltraCAR-T(TM) Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndrome (MDS)
Dec 21, 2018
Exemplar Genetics and Mayo Clinic Launch Joint Venture Focused on Development of Human Liver Cells to Advance Medical Research
Dec 20, 2018
Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon